Ardelyx (ARDX) Net Income (2013 - 2026)
Ardelyx's (ARDX) quarterly Net Income came in at -$37.6 million in Q1 2026, up 8.6% YoY from -$34.6 million in Q1 2025, and down 9139.56% on a QoQ basis from -$407000.0 in Q4 2025.
Ardelyx (ARDX) Net Income (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Net Income data on file, last reported at -$37.6 million in Q1 2026.
- Quarterly Net Income rose 8.6% year-over-year to -$37.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.1 million (down 7.99% YoY) and the FY2025 annual result came in at -$61.6 million, down 57.4% from the prior year.
- Net Income slipped to -$37.6 million in Q1 2026, from -$407000.0 in the prior quarter.
- In the past five years, Net Income ranged from a high of $10.7 million in Q4 2022 to a low of -$41.1 million in Q1 2025.
- A 5-year average of -$16.0 million and a median of -$19.1 million in 2025 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income jumped 129.52% — and 2023, when it tumbled 369.3%.
- Tracing ARDX's Net Income over 5 years: stood at $10.7 million in 2022, then sank by 369.3% to -$28.8 million in 2023, then soared by 116.13% to $4.6 million in 2024, then slumped by 108.76% to -$407000.0 in 2025, then slumped by 9139.56% to -$37.6 million in 2026.
- The last three Net Income figures came in at -$37.6 million (Q1 2026), -$407000.0 (Q4 2025), and -$969000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -16.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.72 Mn |
| Mar 31, 2026 | -37.61 Mn |
| Dec 31, 2025 | -407,000.00 |
| Sep 30, 2025 | -969,000.00 |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -41.14 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | -16.45 Mn |
| Mar 31, 2024 | -26.52 Mn |
| Dec 31, 2023 | -28.80 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | -17.12 Mn |
| Mar 31, 2023 | -26.77 Mn |
| Dec 31, 2022 | 10.70 Mn |
| Sep 30, 2022 | -22.89 Mn |
| Jun 30, 2022 | -26.94 Mn |
| Mar 31, 2022 | -28.07 Mn |
| Dec 31, 2021 | -36.23 Mn |
| Sep 30, 2021 | -43.59 Mn |